6,7-二氯喹唑啉-2,4(1h,3h)-二酮 | 864293-02-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 6,7-二氯喹唑啉-2,4(1h,3h)-二酮
• 英文名称: 6,7-dichloroquinazoline-2,4(1H,3H)-dione
• 英文别名: 6,7-dichloro-2,4-dioxo-1,2,3,4-tetrahydroquinazoline；6,7-dichloroquinazolin-2,4(1H,3H)-dione；6,7-dichloro-1H-quinazoline-2,4-dione
• CAS: 864293-02-7
• 化学式: C₈H₄Cl₂N₂O₂
• 分子量: 231.038
• InChiKey: MSHRSAAVGBWFMI-UHFFFAOYSA-N

物化性质

• 密度：
  1.590±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6,7-二氯喹唑啉-2,4(1h,3h)-二酮 在 sodium hydride 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 5.0h， 生成 N-(3-bromophenyl)-2,6,7-trichloro-N-methylquinazolin-4-amine
  参考文献：
  名称：

  [EN] DIACYLGLYCEROL KINASE MODULATING COMPOUNDS
  [FR] COMPOSÉS MODULANT LA DIACYLGLYCÉROL KINASE

  摘要：

  本公开提供了调节二酰基甘油激酶的化合物以及用于治疗癌症（包括实体瘤）和病毒感染（如HIV或乙型肝炎病毒感染）的药物组合物。这些化合物可以单独使用或与其他药物联合使用。

  公开号：

  WO2021130638A1
• 作为产物：
  描述：

  4,5-二氯氨茴酸 、 尿素 在 sodium hydroxide 作用下， 以 水 为溶剂， 反应 6.08h， 以94%的产率得到6,7-二氯喹唑啉-2,4(1h,3h)-二酮
  参考文献：
  名称：

  Quinazolines and related heterocyclic compounds and their therapeutic use

  摘要：

  该化合物的公式为X是CR1或N；Y是CR3或N；R1、R3、R4、R5和R6分别独立地为H、F、Cl、Br、I或一个可能含有一个或多个杂原子的碳氢基团；R7是一个包括一个或多个N原子的杂环基团；R'是Rx或NRyRz，其中Rx、Ry和Rz分别为H或相同或不同的基团，包括由Ry和Rz与N原子形成的环基团，最多包含20个碳原子，且可选地包含最多3个进一步从N、O和S中选择的杂原子；或其药用盐、酯或溶剂化合物具有治疗用途。

  公开号：

  EP2077263A1

文献信息

• Quinazolines and related heterocyclic compounds, and their therapeutic use
  申请人：Smits Rogier Adriaan

  公开号：US08530486B2

  公开（公告）日：2013-09-10

  A compound of the formula (I) wherein X is CR1 or N; Y is CR3 or N; R1, R3, R4, R5 and R6 are independently H, F, Cl, Br, I, or a hydrocarbon group which optionally contains one or more heteroatoms; R7 is a heterocyclic group including one or more N atoms; R′ is Rx or NRyRz wherein Rx, Ry and Rz are each H or the same or different groups, including cyclic groups formed by Ry and Rz with the N atom, of up to 20 C atoms and optionally including up to 3 further heteroatoms selected from N, O and S; or a pharmaceutically acceptable salt, ester or solvate thereof.

  化合物的公式（I），其中X是CR1或N; Y是CR3或N; R1、R3、R4、R5和R6独立地为H、F、Cl、Br、I或含有一个或多个杂原子的碳氢基团; R7是包括一个或多个N原子的杂环基团; R′是Rx或NRyRz，其中Rx、Ry和Rz分别为H或相同或不同的基团，包括由Ry和Rz与N原子形成的环状基团，长度最长可达20个C原子，并且可选地包括最多3个从N、O和S中选择的进一步杂原子; 或其药学上可接受的盐、酯或溶剂化物。
• Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use
  申请人：Smits Rogier Adriaan

  公开号：US20100298322A1

  公开（公告）日：2010-11-25

  A compound of the formula (I) wherein X is CR 1 or N; Y is CR 3 or N; R 1 , R 3 , R 4 , R 5 and R 6 are independently H, F, Cl, Br, I, or a hydrocarbon group which optionally contains one or more heteroatoms; R 7 is a heterocyclic group including one or more N atoms; R′ is R x or NR y R z wherein R x , R y and R z are each H or the same or different groups, including cyclic groups formed by R y and R z with the N atom, of up to 20 C atoms and optionally including up to 3 further heteroatoms selected from N, O and S; or a pharmaceutically acceptable salt, ester or solvate thereof.

  化合物的式子 (I)，其中 X 是 CR1 或 N；Y 是 CR3 或 N；R1、R3、R4、R5 和 R6 分别是 H、F、Cl、Br、I 或一个含有一个或多个杂原子的碳氢基团；R7 是一个含有一个或多个 N 原子的杂环基团；R′ 是 Rx 或 NRyRz，其中 Rx、Ry 和 Rz 分别是 H 或相同或不同的基团，包括由 Ry 和 Rz 与 N 原子形成的环状基团，具有高达 20 个 C 原子并且可选地包括最多 3 个来自 N、O 和 S 的进一步杂原子；或其药学上可接受的盐、酯或溶剂化物。
• Process for producing 1-substituted tetrahydroquinazolindionen
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：EP0775697A1

  公开（公告）日：1997-05-28

  A process for producing a 1-substituted tetrahydroquinazoline represented by the formula (III): wherein Z represents a methylene group which is optionally substituted by an alkyl group; R6 represents an alkyl group or an aralkyl group; R1 and R2 independently represent a hydrogen atom, a halogen atom, a nitro group, an azido group, an alkyl group, an alkenyl group, an aralkyl group, an alkoxy qroupm, an alkoxycarbonyl group, an acyloxy group, or an amino group represented by XNR4R5in which X represents a direct bond, an alkylene group or a carbonyl group, and N, R4 and R5 may form together a five- or six-membered heterocyclic ring or R4 and R5 independently represent an alkyl group or an acyloxy alkyl group; and R3 represents a hydrogen atom, a halogen atom, a nitro group, an azido group, an alkyl group, an alkenyl group, an aralkyl qroup, an alkoxy group, or an alkoxycarbonyl group which comprises reacting tetrahydroquinazolines represented by the formula (I): wherein R1, R2 and R3 are as defined above with hexamethyldisilazane; and reacting the resultant product with a chloroalkanoate represented by the formula (II):         C1-Z-CO-O-R6     (II) wherein Z and R6 are as defined above in the presence of an iodide of an alkaline metal, followed by desilylation.

  一种生产由式(III)代表的1-取代的四氢喹唑啉的工艺： 其中 Z 代表任选被烷基取代的亚甲基；R6 代表烷基或芳烷基；R1和R2各自代表氢原子、卤素原子、硝基、叠氮基、烷基、烯基、芳烷基、烷氧基、烷氧羰基、酰氧基或由XNR4R5代表的氨基，其中X代表直接键、亚烷基或羰基，N、R4和R5可共同形成五元或六元杂环，或R4和R5各自代表烷基或酰氧基烷基；R3代表氢原子、卤素原子、硝基、叠氮基、烷基、烯基、芳烷基、烷氧基或烷氧基羰基，包括反应式(I)代表的四氢喹唑啉： 其中 R1、R2 和 R3 如上文所定义，与六甲基二硅氮烷反应；并将生成物与式 (II) 所代表的氯代烷酸酯反应： C1-Z-CO-O-R6 (II) 其中 Z 和 R6 如上文所定义，在碱金属碘化物存在下反应，然后脱硅。
• Process for producing 1-substituted tetrahydroquinazolines
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP0878468B1

  公开（公告）日：2003-03-19
• Synthesis and QSAR of Quinazoline Sulfonamides As Highly Potent Human Histamine H₄ Receptor Inverse Agonists
  作者：Rogier A. Smits、Maristella Adami、Enade P. Istyastono、Obbe P. Zuiderveld、Cindy M. E. van Dam、Frans J. J. de Kanter、Aldo Jongejan、Gabriella Coruzzi、Rob Leurs、Iwan J. P. de Esch

  DOI：10.1021/jm901379s

  日期：2010.3.25

  Hit optimization of the class of quinazoline containing histamine H-4 receptor (H4R) ligands resulted in a sulfonamide substituted analogue with high affinity for the H4R. This moiety leads to improved physicochemical properties and is believed to probe a distinct H4R binding pocket that was previously identified using pharmacophore modeling. By introducing a variety of sulfonamide substituents, the H4R affinity was optimized. The interaction of the new ligands, in combination with a set of previously published quinazoline compounds, was described by a QSAR equation. Pharmacological studies revealed that the sulfonamide analogues have excellent H4R affinity and behave as inverse agonists at the human H4R. In vivo evaluation of the potent 2-(6-chloro-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-N-phenylethanesulfonamide (54) (pK(i) = 8.31 +/- 0.10) revealed it to have anti-inflammatory activity in an animal model of acute inflammation.